Harmony Biosciences Holdings Inc.is a pharmaceutical company. It engages in developing and commercializing therapies for rare neurological disorders. Harmony Biosciences Holdings Inc.is based in Plymouth Meeting, Pennsylvania.
| Revenue (Most Recent Fiscal Year) | $714.73M |
| Net Income (Most Recent Fiscal Year) | $145.49M |
| PE Ratio (Current Year Earnings Estimate) | 10.92 |
| PE Ratio (Trailing 12 Months) | 10.70 |
| PEG Ratio (Long Term Growth Estimate) | 0.44 |
| Price to Sales Ratio (Trailing 12 Months) | 2.37 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.34 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 11.55 |
| Pre-Tax Margin (Trailing 12 Months) | 27.90% |
| Net Margin (Trailing 12 Months) | 22.50% |
| Return on Equity (Trailing 12 Months) | 24.88% |
| Return on Assets (Trailing 12 Months) | 17.01% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.75 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.72 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.18 |
| Inventory Turnover (Trailing 12 Months) | 27.74 |
| Book Value per Share (Most Recent Fiscal Quarter) | $11.56 |
| Earnings per Share (Most Recent Fiscal Quarter) | $0.87 |
| Earnings per Share (Most Recent Fiscal Year) | $2.51 |
| Diluted Earnings per Share (Trailing 12 Months) | $3.18 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 57.60M |
| Free Float | 44.00M |
| Market Capitalization | $1.96B |
| Average Volume (Last 20 Days) | 0.94M |
| Beta (Past 60 Months) | 0.85 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 23.60% |
| Percentage Held By Institutions (Latest 13F Reports) | 86.23% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |